Biophytis (EPA:ALBPS) | Finanzwire

Basculer en Français

10185	Companies
209648	Keywords
139775	Articles
111152	Press releases

Home
Companies
Biophytis

REGULATED PRESS RELEASE

published on 01/14/2025 at 07:00, 1 year 2 months ago

Biophytis Enters Exclusive Negotiations with a Chinese Pharmaceutical Company to License BIO101
Biophytis enters exclusive negotiations with a Chinese pharmaceutical company to license BIO101 for viral respiratory infections, sarcopenia, and obesity. The potential partnership aims to develop and commercialize the drug in China's growing pharmaceutical market

Biophytis Exclusive Negotiations Chinese Pharmaceutical Company BIO101 License Viral Respiratory Infections
BRIEF

published on 01/08/2025 at 07:05, 1 year 3 months ago

Biophytis Secures €8.6 Million for Obesity Program

Clinical Development Debt Conversion Obesity Program Biophytis Financing New Investors
REGULATED PRESS RELEASE

published on 01/08/2025 at 07:00, 1 year 3 months ago

Biophytis Announces New Cash Contribution and Debt Conversion up to €8.6 million to Finance the Obesity Program
Biophytis announces new cash contribution and debt conversion totaling €8.6 million to finance obesity program. Strategic financial transaction strengthens company's financial structure for future development

Biophytis Financial Transaction Debt Conversion Obesity Program Cash Contribution
BRIEF

published on 01/06/2025 at 08:35, 1 year 3 months ago

Biophytis Temporarily Suspends Trading of Shares Before Refinancing

Biophytis Biotechnology Refinancing Age-related Diseases Trading Suspension
REGULATED PRESS RELEASE

published on 01/06/2025 at 08:30, 1 year 3 months ago

Biophytis announces temporary suspension of the listing of its shares and share warrants prior to the completion of a refinancing transaction
Biophytis temporarily suspends listing of shares and share warrants prior to refinancing transaction. Trading to resume soon

Biophytis Shares Refinancing Listing Suspension
BRIEF

published on 12/24/2024 at 07:05, 1 year 3 months ago

Biophytis to Attend 2025 JP Morgan Healthcare Conference in San Francisco

Biophytis Biotechnology Investment Opportunities JP Morgan Healthcare Conference Obesity Innovation
REGULATED PRESS RELEASE

published on 12/24/2024 at 07:00, 1 year 3 months ago

Biophytis Will Be In San Franscico During The 2025 JP Morgan Healthcare Conference
Biophytis to attend 2025 JP Morgan Healthcare Conference in San Francisco and participate in Sachs Conference and BIO@JPM Week. The company focuses on developing treatments for age-related diseases

Biophytis Biotechnology Age-related Diseases San Francisco JP Morgan Healthcare Conference
BRIEF

published on 12/23/2024 at 07:05, 1 year 3 months ago

Biophytis Presents Obesity Program at SCWD Congress

Biophytis BIO101 Obesity GLP-1 RAs Quinolia Study
REGULATED PRESS RELEASE

published on 12/23/2024 at 07:00, 1 year 3 months ago

Biophytis showcased the OBA program in obesity at the 17th SCWD international congress
Biophytis presented the OBA program in obesity at the 17th SCWD congress, showcasing positive results of BIO101 in overweight and obese patients, supporting further clinical development

Biophytis Clinical Development BIO101 Obesity OBA Program
BRIEF

published on 12/02/2024 at 07:05, 1 year 4 months ago

Biophytis Engages in SCWD Congress and Hosts Obesity Investor Call

Biophytis Investor Call Obesity Treatment GLP-1 RA SCWD Congress

Accesswire

Published on 04/10/2026 at 02:15, 9 hours 23 minutes ago

Reminder: Jaguar Health to Host Investor Webcast at 8:30 am Eastern on Friday, April 10, 2026 Regarding Q4 2025 Financials and Company Updates
Published on 04/10/2026 at 01:05, 10 hours 33 minutes ago

Pathfinder Ventures Inc. Announces Tranche Closing of Financing and Extension of Private Placement
Published on 04/10/2026 at 00:00, 11 hours 38 minutes ago

Redwood AI Announces Upgraded Cloud-Based Reactosphere Platform with Enhanced Security and Expanded Core Capabilities
Published on 04/09/2026 at 23:15, 12 hours 23 minutes ago

Digi Power X Enters into Amended and Restated Sales Agreement
Published on 04/09/2026 at 23:05, 12 hours 33 minutes ago

Caldwell Reports Second Quarter Results

View all ACCESSWIRE

EQS Group

Published on 04/10/2026 at 11:25, 12 minutes ago

ANTARES VISION GROUP AT INTERPACK 2026
Published on 04/10/2026 at 11:07, 30 minutes ago

NOTICE OF CALLING OF THE ORDINARY SHAREHOLDERS’ MEETING
Published on 04/10/2026 at 10:45, 52 minutes ago

"In Europe, For Europe": Haier Biomedical Spotlights Full-Scenario Lab Solutions at analytica Munich 2026
Published on 04/10/2026 at 10:44, 53 minutes ago

Edison issues report on Lowland Investment Company (LWI)
Published on 04/10/2026 at 10:00, 1 hour 38 minutes ago

Eckert & Ziegler Secures Patient Access to Critical Eye Cancer Treatment with MDR Certification for Ru-106 Eye Applicators

Les Echos

Published on 04/10/2026 at 10:00, 1 hour 38 minutes ago

Recticel Group’s acoustic materials used in NASA’s Artemis II-mission
Published on 04/10/2026 at 08:45, 2 hours 53 minutes ago

Imerys-press-release-binding-agreement_10-04-2026_VENG
Published on 04/10/2026 at 08:45, 2 hours 53 minutes ago

BAIKOWSKI: 2025 annual results: Business growth and solid profitability including a non-recurring item
Published on 04/10/2026 at 08:30, 3 hours 7 minutes ago

Saint-Gobain has signed an agreement for the sale of its ventilation distribution business in the Nordics
Published on 04/09/2026 at 18:35, 17 hours 3 minutes ago

Availability of proxy documents for the Combined General Meeting of April 30, 2026

View all LES ECHOS COMFI WIRE